CDMO– tag –
-
CDMO Strategies Advance Next-Gen Biopharma: Automated Closed Systems Tackle Manufacturing Shortages
World Pharma Today Global Overview Contract Development and Manufacturing Organizations (CDMO) strategies are evolving towards end-to-end service models to support the surge in next-generation biopharmaceuticals, especially cell and gene... -
European Biotechs Unveil Next-Gen CGT Manufacturing to Cut CAR-T Costs Above €60,000 Per Patient
PharmTech Global Overview European biopharmaceutical companies are spearheading the development of advanced manufacturing technologies to address the high costs and logistical hurdles of Cell and Gene Therapies (CGT). Innovations include... -
Lonza Expands Commercial ADC Payload-Linker Manufacturing Capacity at Visp to Support Growing Oncology Pipeline
BioPharma APAC Switzerland Overview CDMO giant Lonza has announced significant expansion plans for its commercial antibody-drug conjugate (ADC) payload-linker manufacturing capacity at its Visp, Switzerland, site. This strategic investme... -
Lonza Significantly Boosts ADC Manufacturing Capacity at Swiss Visp Site, Expanding Payload-Linker Production and Launching New Commercial Facility by 2028
Fierce Pharma Switzerland Overview Lonza announced a significant expansion of its ADC manufacturing capacity, extending a partnership with a major US drugmaker to meet the growing demand in the antibody-drug conjugate market. At its Visp... -
FDA Manufacturing PreCheck Pilot Program Selects 7 Companies Including Cellares to Streamline and Expedite Cell Therapy Manufacturing Processes
RegMedNet UK Overview The FDA has selected seven companies, including Cellares Corp, FUJIFILM Biotechnologies, and Kriya Therapeutics, for its "Manufacturing PreCheck Pilot Program," designed to streamline cell and gene therapy manufactu... -
Europe’s Biotech Vanguard: Automated, Closed Systems Drive Next-Gen CGT Manufacturing and Decentralized Access
PharmTech.com ヨーロッパ Overview European biotechnology firms are pioneering next-generation manufacturing technologies for cell and gene therapies (CGT), centered on automated, closed systems. These innovations, exemplified by companie... -
Cell Therapy Scale-Up and CDMO Staff Reductions Trigger Critical Process Know-How Loss in Tech Transfer
Drug Discovery and Development USA Overview The scaling of cell therapies, coupled with staffing changes at Contract Development and Manufacturing Organizations (CDMOs), is leading to a significant loss of critical process know-how durin... -
Thermo Fisher Scientific Unveils DynaXS Single-Use Bioreactor and Global Manufacturing Expansion at BIO 2026, Boosting Cell & Gene Therapy Production
Business Wire USA Overview Thermo Fisher Scientific announced significant new manufacturing capabilities and AI-enabled research advancements at BIO International 2026, aiming to strengthen the cell and gene therapy sector. Key highlight... -
Samsung Biologics Expands Bio R&D Center Beyond CDMO Support, Investing in Next-Gen Modalities, AI, and Machine Learning
Korea Biomedical Review (KBR) South Korea Overview Samsung Biologics is significantly expanding its Bio R&D Center beyond traditional Contract Development and Manufacturing Organization (CDMO) support. The company is focusing on thre... -
Sartorius and LFB BIOMANUFACTURING Broaden Partnership to Offer Integrated Cell Line Development-to-GMP Services
PharmaSource Global Overview Sartorius and LFB BIOMANUFACTURING have expanded their strategic collaboration to provide integrated services spanning cell line development to GMP drug substance manufacturing. This partnership aims to simpl...
